Use this form to request a free consultation with a qualified attorney near you.
Your privacy is important to us. Any information submitted to this form is guaranteed safe, secure, and private.
800-889-3898
Raptiva warnings are quite extensive. As a treatment for moderate-to-severe plaque psoriasis, this drug (generic name, efalizumab) is not a first-line choice for psoriasis; rather, it is to be prescribed only for individuals with the kind of psoriasis that can't be treated with topical medications.
Genentech USA, Inc., the manufacturer of Raptiva, states on their Raptiva website that the company has decided to voluntarily stop selling the Raptiva drug, and they warn patients that:
“Pharmacies will only refill prescriptions until Monday June 8, 2009. It is important that you have enough time to plan a change to another treatment before stopping RAPTIVA.”
The reason for the withdrawal of Raptiva from the U.S. market is a potential side effect of this drug — a debilitating, usually fatal brain infection called progressive multifocal leukoencephalopathy (PML). In October 2008, the FDA required that a new, "black box" warning about the Raptiva–PML risk be added to the packaging and prescription information for Raptiva. The withdrawal of Raptiva is the latest development.
Genentech's Raptiva website also warns patients and physicians that stopping Raptiva treatment suddenly can lead to serious side effects. The company advises Raptiva patients to:
As the Warning text that accompanies Raptiva notes, there is no medical intervention that can treat PML, the following symptoms of which progress over days to weeks:
PML is nearly always fatal, and individuals who don't die from PML are left severely disabled.
Have you or a loved one been injured after taking Raptiva? If so, contact us to speak with an experienced Raptiva attorney who specializes in drug recall litigation & lawsuits. Let us help you win the compensation you need and deserve.